Beam Therapeutics Inc. (BEAM) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 2.54B USD. 52-week range 20.23 to 38.26 USD. Data as of 2026-10-09.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, ...